<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1140"/><api:result><api:object category="publication" id="1140" last-affected-when="2024-04-19T00:09:50.72+01:00" last-modified-when="2024-04-19T00:09:50.72+01:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1140" created-when="2010-05-17T13:47:32.267+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2017-12-14</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1140" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10896236" last-modified-when="2020-04-29T00:34:33.243+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>A cohort of 79 previously untreated patients (PUPs) with moderate-severe haemophilia A (baseline Factor VIII &lt; or =2%) were enrolled in a study to evaluate the safety, efficacy and immunogenicity of recombinant factor VIII (r-FVIII, Recombinate). Blood samples were obtained retrospectively from a total 55 PUPs who were investigated for the spectrum of FVIII gene mutations responsible for their haemophilia. FVIII gene inversion mutations were found in 27 (49%) patients. Two patients had partial gene deletions. The remaining 26 patients were then screened for mutations in the FVIII gene coding region using conformation sensitive gel electrophoresis. Point mutations were identified in 22 (85%) of the patients and 14 of these mutations were novel. Study subjects were monitored for the development of FVIII inhibitors throughout the study. A total of 23 of the 73 evaluable subjects (including one subject with a low inhibitor titer at baseline) demonstrated an inhibitor on one or more occasions; 11 (15%) were persistent. Inhibitors were detected in patients with partial gene deletions and inversions and in three of eight patients with missense mutations. No inhibitors were found in 11 patients with small insertions or deletions resulting in an alteration of the protein translation reading frame (frameshift mutations). The results corroborate the observation that mutation type is an important determinant of the propensity to develop inhibitory anti-FVIII antibody.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1119" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1119"/></api:links><api:last-name>Goodeve</api:last-name><api:initials>AC</api:initials><api:first-names>AC</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK. a.goodeve@sheffield.ac.uk</api:line></api:address></api:addresses><api:email-address>a.goodeve@sheffield.ac.uk</api:email-address></api:person><api:person><api:last-name>Williams</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Bray</api:last-name><api:initials>GL</api:initials><api:first-names>GL</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="19170" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/19170"/></api:links><api:last-name>Peake</api:last-name><api:initials>IR</api:initials><api:first-names>IR</api:first-names><api:separate-first-names><api:first-name>I</api:first-name><api:first-name>R</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10896236</api:text></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0340-6245</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974485"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Thromb Haemost</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Antibody Formation</api:keyword><api:keyword scheme="mesh">Autoantibodies</api:keyword><api:keyword scheme="mesh">Chromosome Inversion</api:keyword><api:keyword scheme="mesh">Cohort Studies</api:keyword><api:keyword scheme="mesh">DNA Mutational Analysis</api:keyword><api:keyword scheme="mesh">Drug Evaluation</api:keyword><api:keyword scheme="mesh">Factor VIII</api:keyword><api:keyword scheme="mesh">Frameshift Mutation</api:keyword><api:keyword scheme="mesh">Gene Deletion</api:keyword><api:keyword scheme="mesh">Hemophilia A</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Mutation</api:keyword><api:keyword scheme="mesh">Mutation, Missense</api:keyword><api:keyword scheme="mesh">Point Mutation</api:keyword><api:keyword scheme="mesh">Recombinant Proteins</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>Germany</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>844</api:begin-page><api:end-page>848</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>00060844</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>11</api:day><api:month>12</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record><api:record format="native" id="882256" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10896236" last-modified-when="2021-01-19T17:57:11.957+00:00"><api:citation-count>29</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>A cohort of 79 previously untreated patients (PUPs) with moderate-severe haemophilia A (baseline Factor VIII &lt; or =2%) were enrolled in a study to evaluate the safety, efficacy and immunogenicity of recombinant factor VIII (r-FVIII, Recombinate). Blood samples were obtained retrospectively from a total 55 PUPs who were investigated for the spectrum of FVIII gene mutations responsible for their haemophilia. FVIII gene inversion mutations were found in 27 (49%) patients. Two patients had partial gene deletions. The remaining 26 patients were then screened for mutations in the FVIII gene coding region using conformation sensitive gel electrophoresis. Point mutations were identified in 22 (85%) of the patients and 14 of these mutations were novel. Study subjects were monitored for the development of FVIII inhibitors throughout the study. A total of 23 of the 73 evaluable subjects (including one subject with a low inhibitor titer at baseline) demonstrated an inhibitor on one or more occasions; 11 (15%) were persistent. Inhibitors were detected in patients with partial gene deletions and inversions and in three of eight patients with missense mutations. No inhibitors were found in 11 patients with small insertions or deletions resulting in an alteration of the protein translation reading frame (frameshift mutations). The results corroborate the observation that mutation type is an important determinant of the propensity to develop inhibitory anti-FVIII antibody.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK. a.goodeve@sheffield.ac.uk</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1119" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1119"/></api:links><api:last-name>Goodeve</api:last-name><api:initials>AC</api:initials><api:first-names>AC</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0002-6177-7062</api:identifier></api:identifiers></api:person><api:person><api:last-name>Williams</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Bray</api:last-name><api:initials>GL</api:initials><api:first-names>GL</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="19170" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/19170"/></api:links><api:last-name>Peake</api:last-name><api:initials>IR</api:initials><api:first-names>IR</api:first-names><api:separate-first-names><api:first-name>I</api:first-name><api:first-name>R</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>2567-689X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974485"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10896236</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0340-6245</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974485"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Thrombosis and haemostasis</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Hemophilia A</api:keyword><api:keyword scheme="mesh">Factor VIII</api:keyword><api:keyword scheme="mesh">Recombinant Proteins</api:keyword><api:keyword scheme="mesh">Autoantibodies</api:keyword><api:keyword scheme="mesh">Cohort Studies</api:keyword><api:keyword scheme="mesh">Drug Evaluation</api:keyword><api:keyword scheme="mesh">DNA Mutational Analysis</api:keyword><api:keyword scheme="mesh">Antibody Formation</api:keyword><api:keyword scheme="mesh">Gene Deletion</api:keyword><api:keyword scheme="mesh">Mutation</api:keyword><api:keyword scheme="mesh">Frameshift Mutation</api:keyword><api:keyword scheme="mesh">Mutation, Missense</api:keyword><api:keyword scheme="mesh">Point Mutation</api:keyword><api:keyword scheme="mesh">Chromosome Inversion</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>844</api:begin-page><api:end-page>848</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>6</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>15</api:day><api:month>7</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record><api:record format="native" id="2927383" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1074668163" last-modified-when="2024-04-19T00:09:50.737+01:00"><api:citation-count>52</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:links><api:link type="elements/user" id="1119" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/1119"/></api:links><api:last-name>Goodeve</api:last-name><api:initials>AC</api:initials><api:first-names>AC</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>C</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Royal Hallamshire Hospital</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01313111131.15</api:identifier></api:identifiers></api:person><api:person><api:last-name>Williams</api:last-name><api:initials>I</api:initials><api:first-names>I</api:first-names><api:separate-first-names><api:first-name>I</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01050646361.00</api:identifier></api:identifiers></api:person><api:person><api:last-name>Bray</api:last-name><api:initials>GL</api:initials><api:first-names>GL</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="19170" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/19170"/></api:links><api:last-name>Peake</api:last-name><api:initials>IR</api:initials><api:first-names>IR</api:first-names><api:separate-first-names><api:first-name>I</api:first-name><api:first-name>R</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01224773763.79</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1055/s-0037-1613931</api:text><api:links><api:link type="doi" href="http://doi.org/10.1055/s-0037-1613931"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1055/s-0037-1613931"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10896236</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>8.55</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0340-6245</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974485"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>06</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Thrombosis and Haemostasis</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="rcdc">Genetics</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="mesh">Antibody Formation</api:keyword><api:keyword scheme="mesh">Autoantibodies</api:keyword><api:keyword scheme="mesh">Chromosome Inversion</api:keyword><api:keyword scheme="mesh">Cohort Studies</api:keyword><api:keyword scheme="mesh">DNA Mutational Analysis</api:keyword><api:keyword scheme="mesh">Drug Evaluation</api:keyword><api:keyword scheme="mesh">Factor VIII</api:keyword><api:keyword scheme="mesh">Frameshift Mutation</api:keyword><api:keyword scheme="mesh">Gene Deletion</api:keyword><api:keyword scheme="mesh">Hemophilia A</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Mutation</api:keyword><api:keyword scheme="mesh">Mutation, Missense</api:keyword><api:keyword scheme="mesh">Point Mutation</api:keyword><api:keyword scheme="mesh">Recombinant Proteins</api:keyword></api:keywords></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>14</api:day><api:month>12</api:month><api:year>2017</api:year></api:date></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>844</api:begin-page><api:end-page>848</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Thieme</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>1.04</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Relationship between Factor VIII Mutation Type and Inhibitor Development in a Cohort of Previously Untreated Patients Treated with Recombinant Factor VIII (Recombinate™)</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antibody Formation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Autoantibodies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Chromosome Inversion</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cohort Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">DNA Mutational Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Drug Evaluation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Factor VIII</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Frameshift Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Gene Deletion</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Hemophilia A</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mutation, Missense</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Point Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Recombinant Proteins</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Hemophilia A</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Factor VIII</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Recombinant Proteins</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Autoantibodies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cohort Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Drug Evaluation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">DNA Mutational Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antibody Formation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Gene Deletion</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Frameshift Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mutation, Missense</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Point Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Chromosome Inversion</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Genetics</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antibody Formation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Autoantibodies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Chromosome Inversion</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cohort Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">DNA Mutational Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Drug Evaluation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Factor VIII</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Frameshift Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Gene Deletion</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Hemophilia A</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mutation, Missense</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Point Mutation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Recombinant Proteins</api:keyword><api:keyword scheme="for" origin="issn-inferred">1102 Cardiorespiratory Medicine and Haematology</api:keyword><api:keyword scheme="for" origin="issn-inferred">1103 Clinical Sciences</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Cardiovascular System &amp; Hematology</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3201 Cardiovascular medicine and haematology</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3202 Clinical sciences</api:keyword></api:keywords></api:all-labels><api:journal issn="0340-6245" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/974485" title="Thrombosis and Haemostasis"><api:records><api:record source-name="summary"><api:title>Thrombosis and Haemostasis</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1140/relationships"/></api:object></api:result></api:response>